InsidersTradesSigma
RESMED INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the RESMED INC stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, RESMED INC has logged 404 reports. Market capitalisation: €24.3bn. The latest transaction was disclosed on 9 June 2026 (Levée d'options). Among the most active insiders: Farrell Michael J.. The full history is accessible without an account.
404
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€66m
151 ops.
Sell Volume
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 2,688 of 25,804 companies
73.4
score / 100
Value62
Quality85
FCF yld6.8%
Earn yld5.8%
EV/EBITDA13.1x
ROE25%
Gross mgn59%
Net mgn27%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 June 2026
Declarations404 total
4,991 sharesResMed Common StockSEC:0000943819-26-000035:0
4,991 sharesResMed Common StockSEC:0000943819-26-000035:1
4,991 shares@ US$146.341.1% of flowResMed Common StockSEC:0000943819-26-000021:0
4,991 shares@ US$225.50321.7% of flowResMed Common StockSEC:0000943819-26-000021:1
1,000 shares@ US$224.310.7% of flowResMed Common StockSEC:0000943819-26-000020:0
2,000 shares@ US$225.004.1% of flowResMed Common StockSEC:0000943819-26-000019:0
2,000 shares@ US$243.4753.4% of flowReMed Common StockSEC:0001127602-25-015264:0
8,009 shares@ US$101.641.3% of flowResMed Common StockSEC:0001127602-25-013796:0
2,000 shares@ US$242.254.7% of flowResMed Common StockSEC:0001127602-25-013743:0
1,000 shares@ US$215.580.7% of flowResMed Common StockSEC:0001127602-25-011925:0
8,009 shares@ US$101.641.3% of flowResMed Common StockSEC:0001127602-25-011839:0
2,000 shares@ US$219.744.5% of flowResMed Common StockSEC:0001127602-25-011625:0
64 shares@ US$222.862.4% of flowResMed Common StockSEC:0001127602-25-011320:0
169 shares@ US$146.340.3% of flowResMed Common StockSEC:0001127602-25-009051:0
8,009 shares@ US$101.641.4% of flowResMed Common StockSEC:0001127602-25-008958:0
1,000 shares@ US$230.360.8% of flowResMed Common StockSEC:0001127602-25-009188:0
2,000 shares@ US$227.714.7% of flowResMed Common StockSEC:0001127602-25-008593:0
367 shares@ US$211.761.1% of flowResMed Common StockSEC:0001127602-25-007977:0
64 shares@ US$234.102.6% of flowResMed Common StockSEC:0001127602-25-007943:0
1,000 shares@ US$238.980.9% of flowResMed Common StockSEC:0001127602-25-004042:0
8,009 shares@ US$101.641.4% of flowResMed Common StockSEC:0001127602-25-004041:0
2,000 shares@ US$242.115.2% of flowResMed Common StockSEC:0001127602-25-003232:0
64 shares@ US$242.422.8% of flowResMed Common StockSEC:0001127602-25-002880:0
1,000 shares@ US$234.040.9% of flowResMed Common StockSEC:0001127602-25-001067:0
2,000 shares@ US$230.994.9% of flowResMed Common StockSEC:0001127602-25-000487:0
25 of 404 declarations
About RESMED INC
Resmed Inc. (ticker RSMDF) is a global health technology company focused on sleep, breathing, and home-based care. The company is listed on the U.S. NYSE under the symbol RMD, and its headquarters are in San Diego, California, United States. Resmed was founded in 1989 in Australia by Dr. Peter Farrell, initially built around positive airway pressure therapy for sleep apnea, and has since evolved into an international connected-health platform spanning medical devices, software, and digital patient engagement. ([resmed.com](https://www.resmed.com/en-us/about-us/history/?utm_source=openai)) Resmed’s business model is centered on diagnosing, treating, and monitoring sleep and respiratory disorders, especially obstructive sleep apnea and COPD. Its portfolio includes CPAP devices, ventilators, masks, accessories, cloud-connected monitoring tools, and software platforms used by patients, clinicians, and home-care providers. The company emphasizes an integrated approach that combines hardware, digital health software, and care-management solutions, with a clear focus on moving more care out of the hospital and into the home. ([resmed.com](https://www.resmed.com/en-us/about-us/?utm_source=openai)) From a competitive standpoint, Resmed is one of the leading global players in sleep-apnea treatment and home respiratory care. Its international footprint is broad, with management and corporate materials describing operations in more than 140 countries, which gives the company geographic diversification and exposure to both mature and emerging healthcare markets. That scale matters because Resmed’s business benefits from recurring demand for replacement masks, accessories, ongoing patient monitoring, and software-enabled workflow tools. ([investor.resmed.com](https://investor.resmed.com/?utm_source=openai)) Key product families include AirSense and AirCurve devices, AirFit and AirTouch masks, and digital solutions such as myAir. Resmed has also expanded its diagnosis and care pathway capabilities. In April 2025, it launched NightOwl home sleep apnea testing across the United States, and in May 2025 it acquired VirtuOx, an independent diagnostic testing facility specializing in sleep, respiratory, and cardiac conditions. In December 2025, the company announced FDA clearance for Smart Comfort, an AI-enabled feature designed to personalize CPAP comfort settings and help patients start and stay on therapy. ([investor.resmed.com](https://investor.resmed.com/news-events/press-releases/detail/399/resmed-announces-small-easy-to-use-home-sleep-apnea-test-nightowl-now-available-across-the-us?utm_source=openai)) Recent financial updates point to solid momentum. For the first quarter of fiscal 2026, Resmed reported revenue growth of 9% to $1.34 billion, alongside margin expansion and continued operating leverage. For fiscal 2025, the company reported annual revenue of $5.1 billion, up 10% year over year, reinforcing the strength of demand for its sleep-health and breathing-health solutions. For francophone investors, Resmed offers a combination of healthcare defensiveness, recurring revenue characteristics, and a growth profile increasingly supported by digital health innovation. ([newsroom.resmed.com](https://newsroom.resmed.com/news-releases/news-details/2025/Resmed-Inc--Announces-Results-for-the-First-Quarter-of-Fiscal-Year-2026/default.aspx?utm_source=openai))
